UGT2B7: A Potential Drug Target and Biomarker (G7364)

Target Name: UGT2B7

NCBI ID: G7364

UGT2B7

UGT2B7: A Potential Drug Target and Biomarker

Ultrasound-induced plasmonic nanoparticles (UIPNPs) have shown great potential as a drug delivery system due to their ability to encapsulate drugs within a stable and non-toxic core shell. One of the promising applications of UIPNPs is their use as a drug carrier for enhancing the delivery of small molecules, including drugs with difficult bioavailability, such as drugs for the treatment of chronic diseases. One of the families of UIPNPs is the UDP glycosyltransferase 2 (UGT2) family, and the protein of this family, UGT2B7, has emerged as a potential drug target and biomarker due to its unique function in cellular signaling.

Structure and Function

The UGT2 family is a member of the superfamily of N-linked polyketide hydrolases (PKHs) and consists of five distinct isoforms, each with a different N-linked protein domain and a distinct C-terminal region. UGT2B7, also known as UGT2B7A or HSP70伪, is a 21-kDa protein that is expressed in various tissues, including liver, kidney, and heart, and is involved in the detoxification of xenobiotics and other environmentally harmful compounds.

UGT2B7 plays a crucial role in the detoxification of xenobiotics, such as polychlorinated biphenyls (PCBs), which are widely distributed in the environment and have been linked to various health problems, including cancer, reproductive disorders, and neurotoxicity. The detoxification of PCBs is a complex process that involves multiple enzymes, including UGT2B7, and is critical for maintaining the elimination of these toxic compounds from the body.

In addition to its role in drug detoxification, UGT2B7 has also been shown to play a key role in cellular signaling. UGT2B7 is involved in the detoxification of various xenobiotics, including PCBs, which can induce oxidative stress and DNA damage in cells. This is accomplished through the production of reactive oxygen species (ROS), which can cause damage to cellular components and contribute to the development of various diseases, including cancer.

Expression and Modulation

UGT2B7 is highly expressed in various tissues and is a key protein in the detoxification of xenobiotics. It is expressed in the liver, kidney, heart, and pancreas and has been shown to be involved in the detoxification of PCBs, such as 2,4,6-trichloro-2,4,6-trioxaphenyl-1-aminophenol (TCA), as well as other xenobiotics. The expression of UGT2B7 has been shown to be regulated by various factors, including environmental stress, such as temperature and radiation, as well as drugs, including TCA, which is a known activator of UGT2B7.

UGT2B7 has also been shown to be regulated by various signaling pathways, including the TCA-dependent signaling pathway. This pathway is involved in the detoxification of TCA, which can induce oxidative stress and DNA damage in cells. The activity of UGT2B7 has been shown to be dependent on the TCA-dependent signaling pathway, suggesting that UGT2B7 may play a key role in the detoxification of TCA and other xenobiotics.

Drug Targeting

UGT2B7 has been shown to be a potential drug target due to its unique function in cellular signaling and its involvement in the detoxification of xenobiotics. The development of UGT2B7 inhibitors may provide a new strategy for the treatment of various diseases, including cancer, neurotoxicity, and chronic inflammatory disorders.

In addition to its potential as a drug target, UGT2B7 has also been shown to be a potential biomarker for various diseases, including cancer. The detoxification of xenobiotics, including PCBs, is a complex process that

Protein Name: UDP Glucuronosyltransferase Family 2 Member B7

Functions: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile (PubMed:10702251, PubMed:15472229, PubMed:15470161, PubMed:18674515, PubMed:18719240, PubMed:19022937, PubMed:23288867, PubMed:23756265, PubMed:26220143, PubMed:17442341). Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds (PubMed:15470161, PubMed:18674515, PubMed:23756265). Catalyzes the glucuronidation of endogenous steroid hormones such as androgens (epitestosterone, androsterone) and estrogens (estradiol, epiestradiol, estriol, catechol estrogens) (PubMed:2159463, PubMed:15472229, PubMed:18719240, PubMed:19022937, PubMed:23288867, PubMed:26220143, PubMed:17442341). Also regulates the levels of retinoic acid, a major metabolite of vitamin A involved in apoptosis, cellular growth and differentiation, and embryonic development (PubMed:10702251). Contributes to bile acid (BA) detoxification by catalyzing the glucuronidation of BA substrates, which are natural detergents for dietary lipids absorption (PubMed:23756265). Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonist losartan, caderastan and zolarsatan, drugs which can inhibit the effect of angiotensin II (PubMed:18674515). Also metabolizes mycophenolate, an immunosuppressive agent (PubMed:15470161)

The "UGT2B7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UGT2B7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets